Equities Analysts Set Expectations for SGMO FY2030 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for Sangamo Therapeutics in a research report issued on Tuesday, February 10th. HC Wainwright analyst P. Trucchio forecasts that the biopharmaceutical company will post earnings of $0.67 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share.

Several other brokerages have also recently issued reports on SGMO. Weiss Ratings restated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. Finally, Barclays restated an “equal weight” rating and set a $1.00 price objective (down from $5.00) on shares of Sangamo Therapeutics in a research note on Friday, November 7th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $4.33.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $0.38 on Wednesday. The business has a fifty day moving average of $0.43 and a 200 day moving average of $0.51. Sangamo Therapeutics has a 1 year low of $0.35 and a 1 year high of $1.24. The firm has a market capitalization of $127.46 million, a price-to-earnings ratio of -0.86 and a beta of 1.28.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. World Investment Advisors grew its position in shares of Sangamo Therapeutics by 88.5% during the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 20,000 shares during the period. R Squared Ltd acquired a new stake in Sangamo Therapeutics in the second quarter valued at approximately $28,000. XTX Topco Ltd purchased a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $41,000. Engineers Gate Manager LP increased its position in shares of Sangamo Therapeutics by 101.7% in the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 44,078 shares in the last quarter. Finally, Prelude Capital Management LLC acquired a new position in shares of Sangamo Therapeutics during the 3rd quarter worth approximately $67,000. Institutional investors and hedge funds own 56.92% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.